-
Start Preamble
Start Printed Page 30197
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during April 2013. FDA is also informing the public of the availability of summaries for the basis of approval and of environmental review documents, where applicable.
DATES:
This rule is effective May 22, 2013.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, george.haibel@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during April 2013, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Start List of SubjectsTable 1—Original and Supplemental NADAs and ANADAs Approved During April 2013
NADA/ ANADA Sponsor New animal drug product name Action 21 CFR Section FOIA summary NEPA review 200-538 Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland CLINDAMED (clindamycin hydrochloride) Oral Drops Original approval as a generic copy of NADA 135-940 520.447 yes CE 1. 200-551 Putney, Inc., 400 Congress St., Suite 200, Portland, ME 04101 Enrofloxacin Flavored Tablets Original approval as a generic copy of NADA 140-441 520.812 yes CE 1. 1 The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment (EA) or an environmental impact statement (EIS) because it is of a type that does not individually or cumulatively have a significant effect on the human environment. List of Subjects in 21 CFR Part 520
- Animal drugs
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:
Start PartPART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part1. The authority citation for 21 CFR part 520 continues to read as follows:
End Amendment Part[Amended]2. In paragraph (b) of § 520.447, remove “and” and add “, and 061623” after “058829”.
End Amendment Part Start Amendment Part3. Revise § 520.812 to read as follows:
End Amendment PartEnrofloxacin.(a) Specifications. Each tablet contains 22.7, 68.0, or 136.0 milligrams (mg) of enrofloxacin.
(b) Sponsors. See Nos. 000859 and 026637 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs and cats—(1) Amount. Administer orally as a single, daily dose or divided into two equal doses at 12-hour intervals.
(i) Dogs. 5 to 20 mg per kilogram (/kg) (2.27 to 9.07 mg per pound (/lb)) of body weight.
(ii) Cats. 5 mg/kg (2.27 mg/lb) of body weight.
(2) Indications for use. For the management of diseases associated with bacteria susceptible to enrofloxacin.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.
Dated: May 16, 2013.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2013-12134 Filed 5-21-13; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Comments Received:
- 0 Comments
- Effective Date:
- 5/22/2013
- Published:
- 05/22/2013
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final rule.
- Document Number:
- 2013-12134
- Dates:
- This rule is effective May 22, 2013.
- Pages:
- 30197-30197 (1 pages)
- Docket Numbers:
- Docket No. FDA-2013-N-0002
- Topics:
- Animal drugs
- PDF File:
- 2013-12134.pdf
- Supporting Documents:
- » FREEDOM OF INFORMATION SUMMARY NADA 130-185 AMPROL 25% and FLAVOMYCIN Amprolium and Bambermycins
- » FREEDOM OF INFORMATION SUMMARY Application Number 141-422 PACCAL VET-CA1 Paclitaxel for injection Powder for Injection Dog
- » FREEDOM OF INFORMATION SUMMARY NADA141-420 TILDREN tiludronate disodium Powder for injection Horse
- » FREEDOM OF INFORMATION SUMMARY NADA 141-361 PULMOTIL AC Tilmicosin Phosphate Aqueous Concentrate Swine
- » FREEDOM OF INFORMATION SUMMARY NADA 141-246 AQUAFLOR Florfenicol
- » Freedom of Information Summary NADA 141-288 EXCENEL RTU EZ Ceftiofur Hydrochloride
- » Freedom of Information Summary NADA 095-735 RUMENSIN 90 Monensin
- » Freedom of Information Summary NADA 141-406 NEXGARD Afoxolaner Chewable Tablet
- » Freedom of Information Summary ANADA 200-548 ACTOGAIN 45 Ractopamine Hydrochloride Cattle fed in confinement for slaughter
- » Freedom of Information Summary ANADA 200-542 ENGAIN 9 and ENGAIN 5 Ractopamine Hydrochloride Finishing Swine
- CFR: (2)
- 21 CFR 520.447
- 21 CFR 520.812